Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI app aims to ease chemo side effects for breast cancer patients

NCT ID NCT07273812

Symptom relief Sponsor: Dena h. Al-Tameemi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an Arabic-language AI mobile app designed to support women with breast cancer during chemotherapy. The app monitors symptoms, sends medication reminders, and provides educational content. Researchers will compare 130 women who use the app plus usual care to those who receive usual care alone, measuring changes in symptom burden, medication adherence, and quality of life over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based mobile application (AI Breast Cancer Support App)
What this could lead to
If it works, this app could help women with breast cancer better manage chemotherapy side effects, take their medications on time, and feel more informed about their treatment.
What could go wrong
This is a small, early-stage trial (130 participants) testing a support tool, not a treatment. The app is for education only and may not reduce symptoms or improve outcomes for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of breast cancer stages I, II, or III. * Patients must be currently scheduled to initiate their first-ever cycle of chemotherapy. * Age 18 years or older. * Ability to understand and provide informed consent. * Possession of a smartphone (Android or iOS) and functional digital literacy, defined as the ability to independently navigate mobile applications, read on-screen text in Arabic, and input daily health data. (for the intervention group). * Willingness to comply with study procedures and follow-up schedules. * Ability to communicate in Arabic, as the mobile application and chatbot will be developed in Arabic. Exclusion Criteria: * Patients with Stage IV (Metastatic) breast cancer. * Patients receiving concurrent hormonal therapy during the chemotherapy phase, to isolate chemotherapy-induced adverse events. Patients with cognitive impairment or severe psychiatric disorders that would preclude effective interaction with the mobile application or questionnaire completion. * Patients receiving palliative care where symptom management is the sole focus and active chemotherapy is not being administered with curative or life prolonging intent. * Patients participating in other interventional clinical trials that might confound the outcomes of this study. * Patients with severe comorbidities that could significantly impact their ability to participate or bias outcome measures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Accuracy of ai app are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced toxicity Medication Adherence neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Accuracy of ai app Breast cancer Breast neoplasm Chemotherapy-related toxicities Medication adherence Quality of life in cancer patients Symptom management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Oncology Teaching Hospital-Medical City- Baghdad

    RECRUITING

    Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.